Get started
Author

Eugenia N. Ugwuneji

Observed names: Eugenia N. Ugwuneji, Eugenia N Ugwuneji, Eugenia Ugwuneji, Ugwuneji, Eugenia N.
OpenAlex ID: A5083605601
Hypertension Treatment in Nigeria (HTN) Program: rationale and design for a type 2 hybrid, effectiveness, and implementation interrupted time series trial
2022 · Abigail S. Baldridge, Kasarachi Aluka-Omitiran, et al. · Implementation Science Communications · 40
PDF
Characteristics and Patterns of Retention in Hypertension Care in Primary Care Settings From the Hypertension Treatment in Nigeria Program
2022 · Jiancheng Ye, Ikechukwu A. Orji, et al. · JAMA Network Open · 28
PDF
Fixed‐dose combination therapy‐based protocol compared with free pill combination protocol: Results of a cluster randomized trial
2023 · Olutobi A. Sanuade, Boni M. Ale, et al. · Journal of Clinical Hypertension · 11
PDF
Stakeholder perspectives on the demand and supply factors driving substandard and falsified blood pressure lowering medications in Nigeria: a qualitative study
2022 · Grace Shedul, Olutobi Adekunle Sanuade, et al. · BMJ Open · 10
PDF
Supportive supervision visits in a large community hypertension programme in Nigeria: implementation methods and outcomes
2025 · Gabriel Lamkur Shedul, Nanna Ripiye, et al. · BMJ Open Quality · 7
PDF
Abstract 13217: Optimizing Longitudinal Retention in Care Among Patients With Hypertension in Primary Healthcare Settings: Findings From the Hypertension Treatment in Nigeria Program
2022 · Jiancheng Ye, IKECHUKWU ANTHONY A ORJI, et al. · Circulation · 7
Implementation outcomes from the Hypertension Treatment in Nigeria program: results from a type 2 hybrid interrupted time series trial
2025 · Jiancheng Ye, Lisa R. Hirschhorn, et al. · Implementation Science · 6
Effects of a Pragmatic Type 2 Hybrid Interrupted Time Series Trial on Hypertension Treatment and Control in Nigeria
2024 · Dike Ojji, Abigail S. Baldridge, et al. · Research Square · 2
Hypertension Treatment in Nigeria (HTN) Program Rationale and Design for a Type 2 Hybrid, Effectiveness, and Implementation Interrupted Time Series Trial
2022 · Abigail Baldridge, Kasarachi Aluka-Omitiran, et al. · Research Square · 2
PDF
Abstract MP19: Characteristics And Patterns Of Retention In Hypertension Care In Primary Care Settings: Findings From The Hypertension Treatment In Nigeria Program
2022 · Jiancheng Ye, Ikechukwu Orji, et al. · Circulation · 2
Additional file 1 of Implementation outcomes from the Hypertension Treatment in Nigeria program: results from a type 2 hybrid interrupted time series trial
2026 · Ye, Jiancheng, Hirschhorn, Lisa R., et al. · Figshare
Implementation outcomes from the Hypertension Treatment in Nigeria program: results from a type 2 hybrid interrupted time series trial
2026 · Ye, Jiancheng, Hirschhorn, Lisa R., et al. · Figshare
Impact evaluation of the Hypertension Treatment in Nigeria program using the Translational Science Benefits Model
2026 · Guhan Iyer, Nanna Ripiye, et al. · Journal of Clinical and Translational Science
PDF
Design and implementation of a drug revolving fund for hypertension treatment in primary care setting of the Federal Capital Territory, Nigeria
2025 · Grace Julcit Shedul, Eugenia N Ugwuneji, et al. · BMJ Global Health
PDF
Abstract P099: Fixed-dose Combination Therapy-based Protocol Compared With Nigeria’S National Hypertension Treatment Protocol: Results Of A Cluster Randomized Trial
2022 · Olutobi Sanuade, Boni Ale, et al. · Circulation
Works count: 23
Citation count: 115
H-index: 6
I10-index: 4
Year
Topic
Type